-
InterMune's entry, Actimmune, suppresses production of TGF-beta by disrupting the signals inside the factorylike fibroblast cells that make it.
FORBES: Scar Wars
-
InterMune, however, is not betting everything on off-label use of Actimmune.
FORBES: InterMune Gets Around The FDA
-
The results of that measurement were not significant, but researchers noticed something that might be more encouraging: Patients taking Actimmune were less like to die from IPF.
FORBES: InterMune Gets Around The FDA
-
On his doctor's advice he takes thrice-weekly injections of Actimmune, a medication that has been approved to treat such diseases as osteopetrosis, a bone disease affecting children.
FORBES: Scar Wars
-
The 330-patient study InterMune just unveiled was designed to find out if IPF sufferers who took Actimmune saw their lung capacity decrease less than those who did not take the drug.
FORBES: InterMune Gets Around The FDA
-
InterMune (nasdaq: ITMN - news - people ), the publicly held biotech boutique in Brisbane, Calif. that makes Actimmune, is conducting trials aimed at proving the drug's effectiveness in treating IPF.
FORBES: Scar Wars
-
Actimmune is already such a treatment.
FORBES: Magazine Article